TAKEAIR
ActiveSummary
The computed 12-month bankruptcy probability of TAKEAIR is 1.8% (moderate). The annual accounts of TAKEAIR for financial year 2025 show a net loss of 65% of the equity at the start of that year. The 2025 annual accounts show equity of €225,619 and a net result of -€414,075. Equity fluctuates too strongly from year to year to read a trend from it. Its solvency ranks better than 30% of 62 sector peers (NACE 21, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 05-07-2016 Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21100and 7 others
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 30-09-2021
- Establishment unit
- 2.278.002.042 9700 Oudenaarde, since 01-07-2018
- Financial year end
- 30 June
- Peppol
- Reachable since 04-05-2026
Board and ownership
- SANTENS JohanDirector · since 28-09-2023
- SANTENS Frank Lieven Maria SylvainDirector
- Holdings
- Shares in 1 company TakeAirLabs
Financial position
- Bankruptcy probabilitywithin 12 months
- 1.8%
- Gross margin
- -€241,328
- ▼ 5,878%
- Loss
- €414,075
- ▼ 35.6%
- Equity
- €225,619
- ▼ 64.7%
- Total assets
- €1.5m
- ▲ 9.1%
- Staff
- ≈ 1.2 FTE
- estimated
Score breakdownraises riskLoss of €414,075, the second in a row (financial year 2025)1 change of registered office in 24 months1 of the last 3 accounts latelowers riskSize: total assets €1.5mShow the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 37% of them on solvency, 7% on liquidity, 13% on profitability and 13% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 25 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Registered office moved to OudenaardeResignations: Johnston Donald Blair (director) and Pannecoucke Jo (director)
- · Gazette deed Capital increase of €2,147,140.57 to €2,565,740.57
- · Gazette deed Registered office moved to Gent ForeestelaanAppointments: PANNECOUCKE Jo Pol, SANTENS Frank Lieven Maria Sylvain and SANTENS Johan
Comparable companies
These companies have the same main activity as TAKEAIR: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €688,000 and €3.9m, founded between 2013 and 2022.
| Company | Total assets | Gross margin |
|---|---|---|
| TAKEAIR Oudenaarde | €1.5m | -€0.2m |
| Plant Bio Technologies Gent | €1.0m | -€0.01m |
| BIOSEUTICA BELGIUM Bastogne | €0.8m | -€0.005m |
| Pharma Chemicals France Braine-le-Château | €1.1m | -€0.1m |
| DeuterOncology Liège | €0.7m | -€3.3m |
| IDEVAX Wijnegem | €3.9m | -€0.2m |
| Galenicap Elsene | €1.5m | -€0.4m |
Key facts about TAKEAIR
- What is the company number of TAKEAIR?
- The company number of TAKEAIR is 0658.744.222. The VAT number is the same number with BE in front: BE 0658.744.222.
- Where is TAKEAIR based?
- The registered office is at Arend de Keyserestraat 6B, 9700 Oudenaarde.Company details
- What does TAKEAIR do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of TAKEAIR?
- The legal form of TAKEAIR is Private limited company (BV).
- When was TAKEAIR founded?
- TAKEAIR was founded on 05-07-2016.
- Is TAKEAIR still active?
- Yes, TAKEAIR is an active enterprise in the KBO register.
- How many employees does TAKEAIR have?
- TAKEAIR had an average of 1.5 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does TAKEAIR fall under?
- In its 30-09-2021 annual accounts, TAKEAIR states joint committee 200 (Aanvullend Paritair Comité voor de bedienden).
- What is the turnover of TAKEAIR?
- The annual accounts for financial year 2025 state no turnover. The abbreviated or micro format does not require it.
- Is TAKEAIR profitable?
- In financial year 2025, TAKEAIR made a loss of €414,075.
- Where can I find the annual accounts of TAKEAIR?
- TAKEAIR filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of TAKEAIR due?
- TAKEAIR must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.